Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medicofarma Biotech had a gross margin of -88.24% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medicofarma Biotech Gross Margin % Related Terms
Medicofarma Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDB vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medicofarma Biotech (WAR:MDB) has a Gross Margin % of -88.24% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicofarma Biotech and its competitors. According to the industry distribution chart, Medicofarma Biotech ranks #933 out of 939 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Medicofarma Biotech's Gross Margin % too high?
Medicofarma Biotech's current Gross Margin % is -88.24%. Based on the distribution chart, Medicofarma Biotech ranks #933 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #933 out of 939 companies for Gross Margin %. This places Medicofarma Biotech in the lower half of its industry. The industry median Gross Margin % is 48.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.55, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current Gross Margin % is -88.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.12, compared to a current price of zł0.40 — trading 235% above its estimated fair value. The current Gross Margin % is -88.24%. Medicofarma Biotech's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Gross Margin % is -88.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.40 is trading 235% above its estimated GF Value™ of zł0.12.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
Gross Margin %: -88.24%
GF Value™: zł0.12 vs. price of zł0.40 (235% above fair value)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
35GF Score
Get the complete analysis for WAR:MDB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
